Biomarin Pharmaceutical (BMRN) EV to EBIT (2009 - 2026)
Powered by 
Analysis
Biomarin Pharmaceutical (BMRN) EV to EBIT (2009 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Biomarin Pharmaceutical | 12.88 Bn | 12.01 Bn | 786.91 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 91.96 |
| Mar 31, 2026 | 67.07 |
| Dec 31, 2025 | -221.20 |
| Sep 30, 2025 | -191.17 |
| Jun 30, 2025 | 32.95 |
| Mar 31, 2025 | 54.86 |
| Dec 31, 2024 | 70.64 |
| Sep 30, 2024 | 109.43 |
| Jun 30, 2024 | 119.95 |
| Mar 31, 2024 | 175.54 |
| Dec 31, 2023 | 627.25 |
| Sep 30, 2023 | 509.04 |
| Jun 30, 2023 | 230.88 |
| Mar 31, 2023 | 273.86 |
| Dec 31, 2022 | -1,374.05 |
| Sep 30, 2022 | -5,990.30 |
| Jun 30, 2022 | 364.19 |
| Mar 31, 2022 | 96.12 |
| Dec 31, 2021 | -231.25 |
| Sep 30, 2021 | -246.31 |